Novel Variants in MDC1 are Associated With Severe Oligoasthenoteratozoospermia

Two men with severe OAT carried novel loss-of-function variants in MDC1, a DNA damage checkpoint protein — one ICSI attempt failed

Journal: Clinical Genetics | Published: 2025-09-15 | Type: Case Report | PMID: 40954969 Authors: Liu Xu, Wang Yu, Zhu Fuxi et al. (The Second Affiliated Hospital and Anhui Medical University, China) Funding/COI: National Natural Science Foundation of China; University Natural Foundation of Anhui Educational Committee. COI not disclosed.

Summary

Two patients with severe oligoasthenoteratozoospermia (OAT) — a combined defect in sperm count, motility, and morphology — were found to carry three novel variants in MDC1, a gene encoding a protein central to DNA double-strand break repair. In vitro work confirmed that two of the variants (p.R1882X and p.R1993X) produce truncated or degraded protein that disrupts MDC1's interaction with γH2AX, a key DNA damage signaling partner. One patient attempted ICSI; the outcome was poor.

Claims

• Three novel MDC1 variants identified: NM_014641.3:c.C5977T (p.R1993X), c.C5644T (p.R1882X), and c.A1T (p.M1L)
• p.R1882X causes protein truncation; p.R1993X causes post-truncation protein degradation (confirmed in vitro)
• Immunofluorescence showed disrupted colocalization between truncated MDC1 protein and γH2AX
• One patient and his wife underwent ICSI; result described as "unsatisfactory" — no further clinical detail provided
• Authors claim this is the first report of MDC1 variants in OAT patients

Study Quality

This is a case report of two patients — the smallest unit of clinical evidence. There is no control group, no cohort for variant frequency comparison, and no functional rescue experiment to confirm causality. The in vitro validation (truncation and colocalization assays) adds mechanistic plausibility, but demonstrating that a variant disrupts protein interaction in a cell line is a long way from proving it causes OAT in humans. The MDC1-γH2AX colocalization finding is consistent with known biology but doesn't establish that disrupted colocalization is the proximate cause of spermatogenic failure rather than a correlated finding.

The paper also does not report sperm parameters for either patient beyond the OAT diagnosis, which limits any assessment of phenotype severity or clinical relevance.

Red Flags

• n=2 — no statistical inference is possible or appropriate
• No variant frequency data from population databases (gnomAD, etc.) to contextualize rarity
• "Unsatisfactory" ICSI outcome is unquantified — no embryo quality, fertilization rate, or cycle detail
• COI not disclosed despite multiple institutional affiliations; industry involvement cannot be ruled out
• No rescue experiment — causality between MDC1 variants and OAT phenotype is inferred, not demonstrated
• Funding sources are all institutional/governmental Chinese bodies; no red flags there, but peer review rigor in Clinical Genetics for case reports should be weighed

Strengths

• Mechanistic in vitro validation goes beyond simple variant identification
• Clear protein-level characterization of two distinct truncation mechanisms
• First report linking MDC1 to OAT broadens the genetic diagnostic landscape for this condition
• Multiple Chinese research centers collaborating suggests reasonable clinical access to rare cases

Verdict

Two patients, zero controls, and one failed ICSI cycle. This paper is a genetic case report that documents novel MDC1 variants and provides reasonable in vitro mechanistic support — nothing more. It belongs in the "hypothesis-generating" pile. The MDC1-DNA damage repair axis is biologically credible as a spermatogenesis regulator, and identifying new candidate genes for OAT has real diagnostic utility in theory. But a two-patient case series cannot establish causation, and the clinical outcome data is too sparse to draw any conclusions about reproductive prognosis. Worth noting for genetic counselors cataloguing rare OAT variants; not a basis for clinical inference.